LU91485I2 - Vaccin adjuvant grippal dans lequel l'adjuvant estune émulsion huile-dans-eau comprenant du squalèn e, du DL-a-tocophérol et du polysorbate 80 - Google Patents

Vaccin adjuvant grippal dans lequel l'adjuvant estune émulsion huile-dans-eau comprenant du squalèn e, du DL-a-tocophérol et du polysorbate 80

Info

Publication number
LU91485I2
LU91485I2 LU91485C LU91485C LU91485I2 LU 91485 I2 LU91485 I2 LU 91485I2 LU 91485 C LU91485 C LU 91485C LU 91485 C LU91485 C LU 91485C LU 91485 I2 LU91485 I2 LU 91485I2
Authority
LU
Luxembourg
Prior art keywords
adjuvant
oil
water emulsion
squalene
tocopherol
Prior art date
Application number
LU91485C
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of LU91485I2 publication Critical patent/LU91485I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Edible Oils And Fats (AREA)
LU91485C 1993-12-23 2008-10-15 Vaccin adjuvant grippal dans lequel l'adjuvant estune émulsion huile-dans-eau comprenant du squalèn e, du DL-a-tocophérol et du polysorbate 80 LU91485I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939326253A GB9326253D0 (en) 1993-12-23 1993-12-23 Vaccines

Publications (1)

Publication Number Publication Date
LU91485I2 true LU91485I2 (fr) 2008-12-15

Family

ID=10747069

Family Applications (2)

Application Number Title Priority Date Filing Date
LU91486C LU91486I2 (fr) 1993-12-23 2008-10-15 Emulsion huile-dans-eau comprenant du squalène, duDL-a-tocophérol et du polysorbate 80
LU91485C LU91485I2 (fr) 1993-12-23 2008-10-15 Vaccin adjuvant grippal dans lequel l'adjuvant estune émulsion huile-dans-eau comprenant du squalèn e, du DL-a-tocophérol et du polysorbate 80

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU91486C LU91486I2 (fr) 1993-12-23 2008-10-15 Emulsion huile-dans-eau comprenant du squalène, duDL-a-tocophérol et du polysorbate 80

Country Status (23)

Country Link
US (5) US6146632A (fr)
EP (4) EP1327451B1 (fr)
JP (3) JP4125781B2 (fr)
KR (1) KR100350965B1 (fr)
CN (1) CN1086589C (fr)
AT (3) ATE359818T1 (fr)
AU (3) AU1316495A (fr)
CA (1) CA2179779C (fr)
CY (2) CY2530B1 (fr)
DE (5) DE69434956T2 (fr)
DK (3) DK0735898T3 (fr)
ES (3) ES2129801T3 (fr)
GB (1) GB9326253D0 (fr)
GR (1) GR3029750T3 (fr)
HK (3) HK1057991A1 (fr)
LU (2) LU91486I2 (fr)
NL (2) NL300363I1 (fr)
NZ (2) NZ329661A (fr)
PT (2) PT868918E (fr)
SG (2) SG49257A1 (fr)
SI (3) SI0868918T1 (fr)
WO (2) WO1995017209A1 (fr)
ZA (1) ZA9410176B (fr)

Families Citing this family (567)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ES2283012T3 (es) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US7517952B1 (en) * 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US6645495B1 (en) * 1997-08-29 2003-11-11 Antigenics, Inc. Compositions of saponin adjuvants and excipients
DE69838992T2 (de) * 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
DK1659178T3 (da) 1998-02-05 2010-07-12 Glaxosmithkline Biolog Sa Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein
DE69933200T2 (de) * 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
GB9806095D0 (en) * 1998-03-20 1998-05-20 Smithkline Beecham Biolog Novel compounds
KR100692227B1 (ko) 1998-04-07 2007-03-09 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
WO1999056776A2 (fr) * 1998-05-07 1999-11-11 Corixa Corporation Composition d'adjuvant et procedes d'utilisation de celle-ci
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
BR9912671A (pt) 1998-08-07 2001-05-02 Univ Washington Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
CA2354028A1 (fr) 1998-12-08 2000-06-15 Smithkline Beecham Biologicals S.A. Polypeptides basb041 de neisseria meningitidis et polynucleotides codant ces polypeptides, et leurs utilisations
IL143531A0 (en) 1998-12-08 2002-04-21 Corixa Corp Polypeptides containing an antigenic portion of a chlamydia antigen, dna sequences encoding said polypeptides and pharmaceutical compositions and vaccines containing the same
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
EP1147117B1 (fr) * 1999-02-01 2004-06-16 Eisai Co., Ltd. Compose d'adjuvant immunologique
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
GB2348132B (en) * 1999-03-02 2004-08-04 Nedaa Abdul-Ghani Nasif Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
PT1165778E (pt) 1999-03-11 2007-01-31 Glaxosmithkline Biolog Sa Utilizações de polinucleótidos e polipéptidos casb618
EP1163343B1 (fr) 1999-03-12 2009-12-09 GlaxoSmithKline Biologicals S.A. Polypeptides antigeniques de neisseria meningitidis, et polynucleotides et anticorps protecteurs correspondant
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CZ303653B6 (cs) * 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
TR200102745T2 (tr) * 1999-03-26 2002-05-21 Smithkline Beecham Biologicals S.A. Yeni bileşikler
ES2308976T3 (es) 1999-04-02 2008-12-16 Corixa Corporation Compuestos y metodos para la terapia y el diagnostico del cancer de pulmon.
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
WO2000062800A2 (fr) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Vaccins
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
TR200103266T2 (tr) * 1999-05-13 2002-01-21 American Cyanamid Company Yardımcı kombinasyon formülasyonları
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AU1013701A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
CA2400842C (fr) 2000-02-23 2013-01-15 Smithkline Beecham Biologicals S.A. Nouveaux composes
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1385541B1 (fr) * 2000-04-13 2008-06-18 Corixa Corporation Compositions immunostimulantes comprenant un phosphate d'aminoalkyl glucosaminide et du qs-21
EP1278855B1 (fr) 2000-04-21 2008-03-12 Corixa Corporation Composes et procedes pour le traitement et le diagnostic d'une infection de chlamydia
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
WO2001097847A1 (fr) * 2000-06-16 2001-12-27 Smithkline Beecham Corporation Polynucleotides de liaison a icp27
CA2413959C (fr) 2000-06-20 2015-07-07 Corixa Corporation Proteines de fusion du mycobacterium tuberculosis
WO2002000174A2 (fr) 2000-06-28 2002-01-03 Corixa Corporation Compositions et methodes pour le traitement et le diagnostic du cancer du poumon
PT1296715E (pt) 2000-06-29 2012-01-19 Smithkline Beecham Biolog Composição vacinal multivalente
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
ATE310008T1 (de) 2000-07-31 2005-12-15 Eisai Co Ltd Immunologische adjuvans verbindungen
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2266603B1 (fr) 2000-10-18 2012-09-12 GlaxoSmithKline Biologicals S.A. Vaccins contre le cancer
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP1201250A1 (fr) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
US20020094337A1 (en) * 2000-11-16 2002-07-18 University Of Maryland, Baltimore Prevention of recurrent viral disease
CA2822983C (fr) 2000-11-29 2017-05-09 Xy, Llc Systeme de dissociation de spermatozoides congeles-decongeles porteurs d'un chromosome x de ceux porteurs d'un chromosome y
CA2430379A1 (fr) 2000-12-07 2002-06-13 Chiron Corporation Retrovirus endogenes regules positivement dans le cancer de la prostate
EP1423421A2 (fr) * 2001-01-26 2004-06-02 Walter Reed Army Institute of Research Isolation et purification and purification de vaccin a base de proteine-1 42 merozoite de p. falciparum
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP1988097A1 (fr) 2001-05-09 2008-11-05 Corixa Corporation Compositions et procédés pour le traitement et le diagnostic du cancer de la prostate
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
NZ530315A (en) 2001-07-10 2007-01-26 Corixa Corp Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
CA2454920C (fr) * 2001-07-26 2013-06-25 Otago Innovation Limited Compositions antigeniques
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003053220A2 (fr) 2001-12-17 2003-07-03 Corixa Corporation Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
US7030094B2 (en) * 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
PL209696B1 (pl) 2002-04-19 2011-10-31 Univ Toronto Peptyd, kompozycja peptydowa, kompozycja immunogenna, zastosowania kompozycji immunogennej oraz sposób określania czy związek stanowi inhbitor odkładania się i tworzenia włókienek amyloidu
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
AU2003276679A1 (en) 2002-06-13 2003-12-31 Chiron Corporation Vectors for expression of hml-2 polypeptides
DE60324678D1 (de) 2002-07-18 2008-12-24 Univ Washington N t-lymphozyten und damit identifizierte hsv-antigene
WO2004012751A1 (fr) * 2002-08-02 2004-02-12 Sumitomo Pharmaceuticals Company, Limited Preparation d'un compose bacterien de squelette de paroi cellulaire
KR101239242B1 (ko) 2002-08-02 2013-03-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원 조합물을 포함하는 나이세리아 백신 조성물
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7169548B2 (en) 2002-09-13 2007-01-30 Xy, Inc. Sperm cell processing and preservation systems
WO2004032958A1 (fr) 2002-10-11 2004-04-22 Chiron Srl Vaccins polypeptidiques offrant une large protection contre des lignees de meningocoques hypervirulentes
NZ539509A (en) 2002-10-23 2008-05-30 Glaxosmithkline Biolog Sa Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
EP2279746B1 (fr) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Proteines de surface de neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CA2511907A1 (fr) 2003-01-06 2004-07-22 Wyeth Compositions et procede permettant de diagnostiquer et de traiter les cancers du colon
WO2004067030A2 (fr) 2003-01-30 2004-08-12 Chiron Srl Vaccins injectables contre les multiples serogroupes du meningocoque
DK2305173T3 (en) 2003-03-28 2016-08-22 Inguran Llc Apparatus and method for providing sorted particles
WO2004087204A2 (fr) 2003-04-04 2004-10-14 Pfizer Products Inc. Emulsions microfluidifiees d'huile dans l'eau et compositions de vaccins
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7731967B2 (en) * 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
PL1631264T5 (pl) 2003-06-02 2018-09-28 Glaxosmithkline Biologicals Sa Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2005032584A2 (fr) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Composes
ATE506963T1 (de) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
ES2617062T3 (es) 2004-02-05 2017-06-15 The Ohio State University Research Foundation Péptidos VEGF quiméricos
JP5600375B2 (ja) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
JP5041279B2 (ja) * 2004-04-22 2012-10-03 株式会社 Ｍｂｒ 細菌細胞壁骨格成分を含有する製剤
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
BRPI0510315A (pt) 2004-04-30 2007-10-16 Chiron Srl integração de vacinação com conjugado meningocócico
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP2811027A1 (fr) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Vecteurs alphavirus pour vaccins contre le VRS et le PIV
AU2005285513B2 (en) 2004-05-25 2011-02-24 Oregon Health And Science University SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
AU2005249212B2 (en) 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US8085126B2 (en) * 2004-07-27 2011-12-27 Honeywell International Inc. Identification with RFID asset locator for entry authorization
EP2612679A1 (fr) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Compositions immunogènes pour une bactérie à gram positif telle que streptococcus agalactiae
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP2305294B1 (fr) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Composition immunogène pour la vaccination contre des staphylocoques
DK3312272T3 (da) 2004-10-08 2019-12-02 Us Gov Health & Human Services Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2006066089A1 (fr) 2004-12-15 2006-06-22 Neuralab Limited Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
NZ555937A (en) 2005-01-27 2009-05-31 Childrens Hosp & Res Ct Oak GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
GB0506001D0 (en) * 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Novel use
JP5869744B2 (ja) 2005-03-23 2016-02-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃｄ４ｔ細胞および／または改善された記憶ｂ細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用
EP2392349A3 (fr) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Vaccins contre l'infection à chlamydia
CN101355928B (zh) * 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
ES2381492T3 (es) 2005-04-29 2012-05-28 Glaxosmithkline Biologicals Sa Procedimiento de prevención o tratamiento de infección por M. tuberculosis
WO2006138675A2 (fr) 2005-06-15 2006-12-28 The Ohio State University Research Foundation Peptides her-2
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
ATE530569T1 (de) 2005-07-01 2011-11-15 Forsyth Dental In Ry For Children Fa Assays zum nachweis von tuberkulose- antigenen, und impfstoffe
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
EP1931417A2 (fr) * 2005-09-30 2008-06-18 Transcutaneous Technologies Inc. Systemes d'administration transdermique de medicament, dispositifs, et methodes faisant intervenir de nouveaux excipients pharmaceutiques
KR20080066712A (ko) * 2005-09-30 2008-07-16 티티아이 엘뷰 가부시키가이샤 관능화된 미세바늘 경피 약물 전달 시스템, 장치 및 방법
EP1928539A1 (fr) * 2005-09-30 2008-06-11 Tti Ellebeau, Inc. Systemes, dispositifs et procedes d'apport de medicament transdermique a micro-aiguilles fonctionnalisees
EP2357000A1 (fr) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Immunisations mucosiques et systémiques avec des particules de réplicon à alpha-virus
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052155A2 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
CA2628152C (fr) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
US20110180430A1 (en) * 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
EA014028B1 (ru) * 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP1948139A4 (fr) * 2005-11-18 2012-04-04 3M Innovative Properties Co Compositions pouvant être revêtues, revêtements dérivés de celles-ci et micro-réseaux comprenant de tels revêtements
WO2007097820A2 (fr) * 2005-11-18 2007-08-30 The Ohio State University Research Foundation Produits de gène viral et méthodes de vaccination pour prévenir des maladies virales associées
WO2007081447A2 (fr) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Antigènes de norovirus et de sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2808919C (fr) 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Vaccin comportant des conjugues polysaccharides capsulaires streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20080033398A1 (en) * 2005-12-29 2008-02-07 Transcutaneous Technologies Inc. Device and method for enhancing immune response by electrical stimulation
BRPI0707154B8 (pt) 2006-01-17 2022-12-20 Forsgren Arne composição de vacina
DK1976559T6 (da) 2006-01-27 2020-04-06 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
EP2004226A1 (fr) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Stockage de vaccins antigrippaux sans refrigeration
EP2476434A1 (fr) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Composition immunogène
PL2004220T3 (pl) 2006-03-30 2015-11-30 Zoetis Services Llc Sposoby i kompozycje do szczepienia drobiu
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR061136A1 (es) 2006-06-02 2008-08-06 Glaxosmithkline Biolog Sa Procedimiento
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
JP5275983B2 (ja) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
WO2008094183A2 (fr) * 2006-07-11 2008-08-07 University Of Connecticut Utilisation de souches de plasmodium conditionnelles exemptes de transporteurs de nutriments dans la vaccination anti-paludique
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
KR101696727B1 (ko) * 2006-07-17 2017-01-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 백신
PL2422810T3 (pl) 2006-07-17 2015-03-31 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
BRPI0715581A2 (pt) 2006-07-18 2013-04-24 Glaxosmithkline Biolog Sa proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008012538A2 (fr) 2006-07-25 2008-01-31 The Secretary Of State For Defence Souche de vaccin vivant
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
EP2066341B1 (fr) * 2006-09-01 2015-07-15 CSL Limited Procede visant a provoquer ou a induire une reponse immunitaire
AU2007293673B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
CA2663196A1 (fr) 2006-09-11 2008-03-20 Novartis Ag Fabrication de vaccins contre le virus grippal sans utiliser d'oeufs
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2468300B1 (fr) 2006-09-26 2017-12-20 Infectious Disease Research Institute Composition de vaccin contenant un adjuvant synthétique
EP2086582B1 (fr) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccin comprenant une emulsion adjuvante huile en l'eau
CN101522218B (zh) * 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
DK2137210T3 (en) 2007-03-02 2017-01-30 Glaxosmithkline Biologicals Sa Hitherto unknown method and compositions
DK2136836T3 (en) 2007-04-04 2017-04-10 Infectious Disease Res Inst Immunogenic compositions with mycobacterium tuberculosis polypeptides and fusions thereof
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
EP2142211A1 (fr) 2007-05-02 2010-01-13 GlaxoSmithKline Biologicals S.A. Vaccin
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
EP2687228B1 (fr) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccin contenant des conjugues de polysaccharide capsulaire de streptococcus pneumoniae
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2010001284A (es) 2007-08-02 2010-08-31 Biondvax Pharmaceuticals Ltd Vacunas contra la influenza con multiepitope multimerico.
CA2695421A1 (fr) 2007-08-03 2009-02-12 President And Fellows Of Harvard College Antigenes chlamydiens
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
CN101932723B (zh) 2007-09-17 2014-09-10 肿瘤甲基化科学公司 改进的对mage-a表达的检测
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008331800A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
EP2227251A1 (fr) * 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Composition contre la grippe
AU2008335457B2 (en) * 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
ES2626634T3 (es) 2007-12-19 2017-07-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Formas solubles de la glucoproteína F del virus de Hendra y Nipah y usos de la misma
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN104292312A (zh) 2007-12-21 2015-01-21 诺华股份有限公司 链球菌溶血素o的突变形式
US8092813B1 (en) 2007-12-28 2012-01-10 Novartis Ag Polychlorinated biphenyls and squalene-containing adjuvants
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
EP2631245A1 (fr) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Protéines chimères de liaison du facteur H contenant un domaine B hétérologue, et procédés d utilisation associés
WO2009126816A1 (fr) * 2008-04-09 2009-10-15 Ventria Bioscience Production d'ospa pour la lutte contre la maladie de lyme
KR20110009157A (ko) * 2008-04-16 2011-01-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP3329931B1 (fr) 2008-04-18 2022-06-08 The General Hospital Corporation Immunothérapies utilisant des vaccins autoassemblés
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
EP2298344B1 (fr) 2008-06-04 2016-08-17 The Chemo-Sero-Therapeutic Research Institute Utilisation d une particule du virus inactivé de l encéphalite japonaise comme adjuvant
JP5775451B2 (ja) 2008-06-19 2015-09-09 バリエーション バイオテクノロジーズ インコーポレイティド インフルエンザを処置するための組成物および方法
EP2318044B1 (fr) * 2008-08-01 2015-12-02 Gamma Vaccines Pty Limited Vaccins contre la grippe
US11236366B2 (en) 2008-08-28 2022-02-01 Novartis Ag Production of squalene from hyper-producing yeasts
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010036938A2 (fr) 2008-09-26 2010-04-01 Nanobio Corporation Compositions thérapeutiques de nanoémulsion et procédés d'utilisation de celles-ci
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2743904A1 (fr) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Compositions de vaccins contre le cancer et leurs methodes d'utilisation
GB0822001D0 (en) * 2008-12-02 2009-01-07 Glaxosmithkline Biolog Sa Vaccine
EP2356225A1 (fr) 2008-12-03 2011-08-17 Protea Vaccine Technologies Ltd. Fragments de glutamyl-arnt-synthétase (gts)
EP2865389A1 (fr) 2008-12-09 2015-04-29 Pfizer Vaccines LLC Vaccin peptidique IgE CH3
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
US9884105B2 (en) 2008-12-16 2018-02-06 Ology Bioservices, Inc. Production of viral vaccine
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
AR075437A1 (es) * 2009-02-17 2011-03-30 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
KR20120002534A (ko) 2009-03-17 2012-01-05 엠디엑스헬스 에스에이 유전자 발현의 향상된 검출
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
PL2510947T3 (pl) 2009-04-14 2016-09-30 Kompozycje do immunizacji przeciwko Staphylococcus aureus
WO2010125480A1 (fr) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Vaccin anti-pneumococcique et ses utilisations
WO2010132833A1 (fr) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Compositions vaccinales contre streptococcus et méthodes d'utilisation associées
JP2012528106A (ja) 2009-05-27 2012-11-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃａｓｂ７４３９構築物
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
EP2442826B1 (fr) 2009-06-15 2015-07-08 National University of Singapore Vaccin contre l'influenza, composition, et procedes d'utilisation
JP6110140B2 (ja) 2009-06-16 2017-04-05 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ナノエマルションワクチン
WO2011005772A1 (fr) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Procédés pour préparer des vésicules et formulations produites à partir de ces procédés
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
DK3178490T3 (da) 2009-07-15 2022-06-20 Glaxosmithkline Biologicals Sa RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse
CN102770443A (zh) 2009-07-16 2012-11-07 诺华有限公司 脱毒大肠杆菌免疫原
EP2453903B1 (fr) 2009-07-17 2016-08-17 Industry Academic Cooperation Foundation, Hallym University Compositions immunostimulatrices comprenant des oligonucléotides et épitopes encapsulés par liposome
KR20130127547A (ko) 2009-07-30 2013-11-22 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011024072A2 (fr) 2009-08-27 2011-03-03 Novartis Ag Polypeptides hybrides contenant des séquences fhbp à méningocoques
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
SG179037A1 (en) * 2009-09-10 2012-04-27 Merial Ltd New vaccine formulations comprising saponin-containing adjuvants
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CA2779798C (fr) 2009-09-30 2019-03-19 Novartis Ag Conjugaison de polysaccharides capsulaires de staphylococcus aureus de type 5 et de type 8
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
KR20120088721A (ko) 2009-10-09 2012-08-08 씨바이오 리미티드 샤페로닌 10 변이체
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (fr) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae
US20110159031A1 (en) 2009-12-22 2011-06-30 Baxter International Inc. Vaccine to Influenza A Virus
SG10201408505SA (en) 2009-12-22 2015-02-27 Celldex Therapeutics Inc Vaccine compositions
WO2011080595A2 (fr) 2009-12-30 2011-07-07 Novartis Ag Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
EP2353609A1 (fr) 2010-02-04 2011-08-10 Sanofi Pasteur Compositions et procédés d'immunisation
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
CN102869377A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
JP2013522231A (ja) 2010-03-11 2013-06-13 イミューン デザイン コーポレイション インフルエンザのためのワクチン
AU2011231574A1 (en) 2010-03-26 2012-10-11 Glaxosmithkline Biologicals S.A. HIV vaccine
ES2910199T3 (es) 2010-03-30 2022-05-11 Childrens Hospital & Res Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011127316A1 (fr) 2010-04-07 2011-10-13 Novartis Ag Procédé de génération de pseudo-particules virales de parvovirus b19
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
PL3170508T3 (pl) 2010-06-04 2020-04-30 Wyeth Llc Preparaty szczepionek
EP2942061A3 (fr) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Vaccin peptidique ige ch3
WO2011154863A1 (fr) 2010-06-07 2011-12-15 Pfizer Inc. Peptides her-2 et vaccins
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
WO2012006367A2 (fr) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions et méthodes pour traiter la grippe
US20130171185A1 (en) 2010-07-06 2013-07-04 Ethan Settembre Norovirus derived immunogenic compositions and methods
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20130259948A1 (en) 2010-09-21 2013-10-03 National Institute Of Immunology Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CA2812893A1 (fr) 2010-09-27 2012-04-05 Glaxosmithkline Biologicals S.A. Vaccin
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
WO2012057904A1 (fr) 2010-10-27 2012-05-03 Infectious Disease Research Institute Antigènes du mycobacterium tuberculosis et leurs combinaisons présentant une séroréactivité élevée
WO2012064659A1 (fr) 2010-11-08 2012-05-18 Infectious Disease Research Institute Vaccins comprenant des polypeptides d'hydrolase nucléosidique et de stérol 24-c-méthyltransférase (smt) non spécifiques destinés à traiter et à diagnostiquer la leishmaniose
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
EP2646459B1 (fr) 2010-12-02 2020-01-08 Bionor Immuno AS Conception d'échafaudage peptidique
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EP2655389A2 (fr) 2010-12-24 2013-10-30 Novartis AG Composés
CN103347892B (zh) 2011-01-06 2016-11-02 比奥诺尔免疫有限公司 单体和多聚体免疫原性肽
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
EP3527224A1 (fr) 2011-01-26 2019-08-21 GlaxoSmithKline Biologicals S.A. Régime d'immunisation contre le vrs
WO2012100302A1 (fr) 2011-01-27 2012-08-02 Gamma Vaccines Pty Limited Vaccins associés
CN103517713A (zh) 2011-02-22 2014-01-15 彼昂德瓦克斯医药有限公司 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
WO2012131504A1 (fr) 2011-03-02 2012-10-04 Pfizer Inc. Vaccin à base de pcsk9
WO2012135177A2 (fr) 2011-03-29 2012-10-04 Uab Research Foundation Procédés et compositions permettant d'obtenir une protéine il-10 de cytomégalovirus
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
PT2707385T (pt) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Antigénios de f de rsv pré-fusão
US20140072622A1 (en) 2011-05-17 2014-03-13 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
CA2838188C (fr) 2011-06-04 2017-04-18 Rochester General Hospital Research Institute Compositions et procedes associes a la proteine p6 de l'haemophilus influenzae
US20150030586A1 (en) 2011-06-21 2015-01-29 Sarah Ellen Warren Compositions and methods for the therapy and diagnosis of cancer
JP6109165B2 (ja) 2011-07-01 2017-04-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヘルペスウイルスワクチンおよび使用方法
EP2736921B1 (fr) 2011-07-25 2018-06-27 GlaxoSmithKline Biologicals SA Compositions et procédés d'évaluation de l'immunogénicité fonctionnelle de vaccins contre un parvovirus
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
EP2747779A4 (fr) 2011-08-22 2015-04-08 Nanobio Corp Vaccin contre le virus de l'herpès simplex sous forme de nanoémulsion
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US9561271B2 (en) 2011-09-09 2017-02-07 Nanobio Corporation Nanoemulsion respiratory syncytial virus (RSV) subunit vaccine
WO2013038375A2 (fr) 2011-09-14 2013-03-21 Novartis Ag Procédés de production de glycoconjugués de saccharide-protéine
WO2013038385A2 (fr) 2011-09-14 2013-03-21 Novartis Ag Combinaison de vaccin contre escherichia coli
EP2758432B1 (fr) 2011-09-16 2019-03-06 UCB Biopharma SPRL Anticorps neutralisants contre les toxines principales tcda et tcdb de clostridium difficile
EP2780034A1 (fr) 2011-11-14 2014-09-24 Crucell Holland B.V. Immunisation primovaccination-rappel hétérologue à l'aide de vaccins à base du virus de la rougeole
CN108864291A (zh) 2011-11-23 2018-11-23 拜奥文斯瑞有限公司 重组蛋白及其治疗用途
WO2013083753A2 (fr) 2011-12-07 2013-06-13 Institut Pasteur Identification d'un virus porcin de type paréchovirus et applications
SG11201402375VA (en) 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
CA2894442C (fr) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions et methodes de traitement d'infections virales
WO2013108272A2 (fr) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Vaccin antipaludique ciblant le stade sanguin
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
AU2013224026A1 (en) 2012-02-24 2014-08-21 Novartis Ag Pilus proteins and compositions
US20130236484A1 (en) 2012-03-08 2013-09-12 Detectogen Inc. Leishmaniasis antigen detection assays and vaccines
ES2732229T3 (es) 2012-03-23 2019-11-21 Pitney Pharmaceuticals Pty Ltd Inhibidores de cinasa para el tratamiento del cáncer
GB201205189D0 (en) 2012-03-23 2012-05-09 Glaxosmithkline Biolog Sa Novel medical use
EP2833900B1 (fr) 2012-04-01 2018-09-19 Technion Research & Development Foundation Limited Peptides d'inducteur de métalloprotéinase de matrice extracellulaire (emmprin) et anticorps de liaison
WO2013151764A1 (fr) 2012-04-02 2013-10-10 The University Of North Carolina At Chapel Hill Procédés et compositions pour des épitopes du virus de la dengue
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
RU2727476C2 (ru) 2012-04-26 2020-07-21 Новартис Аг Антигены и антигенные композиции
EP2659908A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (fr) 2012-05-01 2013-11-06 Affiris AG Compositions
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
EP3388835B1 (fr) 2012-05-16 2020-04-01 Immune Design Corp. Vaccins contre le hsv-2
JP2015518845A (ja) 2012-05-22 2015-07-06 ノバルティス アーゲー 髄膜炎菌血清群ｘコンジュゲート
EP2666785A1 (fr) 2012-05-23 2013-11-27 Affiris AG Vaccins basés sur la protéine complément C5a
CA2875683A1 (fr) 2012-06-05 2013-12-12 The Australian National University Vaccination avec des antagonistes de l'interleukine-4
EP2859011B1 (fr) 2012-06-06 2019-12-11 Bionor Immuno AS Peptides d'origine virale pour usage en tant qu'immunogènes or réactifs de dépistage
SG11201500439RA (en) 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
JP2015524421A (ja) 2012-07-24 2015-08-24 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ ワクチン組成物
EP3656396A1 (fr) 2012-08-01 2020-05-27 Bavarian Nordic A/S Vaccins de virus respiratoire syncytial (rsv) d'ankara de virus à vaccin modifié recombinant (mva)
EP4299138A2 (fr) 2012-08-03 2024-01-03 Access to Advanced Health Institute Compositions et méthodes de traitement d'une infection active par le bacille de koch
CN105496999A (zh) 2012-08-06 2016-04-20 皮特尼制药股份有限公司 治疗mTOR通路相关的疾病的化合物
JP2014040396A (ja) * 2012-08-23 2014-03-06 Chemo-Sero-Therapeutic Research Institute 脂質異常症治療薬を含有するアジュバント組成物
EP2703483A1 (fr) 2012-08-29 2014-03-05 Affiris AG Vaccin à base de PCSK9
WO2014043189A1 (fr) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Virus de l'herpès déficients pour la réplication conditionnelle et leur utilisation dans des vaccins
MX363529B (es) 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
EA201590427A1 (ru) 2012-10-02 2015-09-30 Глаксосмитклайн Байолоджикалс С.А. Нелинейные сахаридные конъюгаты
US9855324B2 (en) 2012-10-03 2018-01-02 Glaxosmithkline Biologicals Sa Immunogenic compositions
PL2912186T3 (pl) 2012-10-24 2021-06-14 Platelet Targeted Therapeutics Llc Leczenie ukierunkowane na płytki krwi
ES2826555T3 (es) 2012-11-30 2021-05-18 Glaxosmithkline Biologicals Sa Antígenos de Pseudomonas y combinación de antígenos
WO2014083194A1 (fr) 2012-11-30 2014-06-05 Sanofi Pasteur Procédés d'induction d'anticorps
CN104884081A (zh) 2012-12-05 2015-09-02 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
ES2727686T3 (es) 2012-12-17 2019-10-17 Newsouth Innovations Pty Ltd Tratamiento de enfermedades que implican mucina
WO2014100857A1 (fr) 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccins pour traiter le cancer et compositions pour améliorer l'efficacité des vaccins
CA2900008A1 (fr) 2013-02-07 2014-08-14 Children's Medical Center Corporation Antigenes de proteine qui conferent une protection contre une colonisation et/ou une maladie pneumococcique
JP6873530B2 (ja) 2013-03-15 2021-05-19 イン3バイオ・リミテッドIn3Bio Ltd. 自己組織化合成タンパク質（Ｓｅｌｆ−Ａｓｓｅｍｂｌｉｎｇ Ｓｙｎｔｈｅｔｉｃ Ｐｒｏｔｅｉｎｓ）
BR112015024860B1 (pt) 2013-03-28 2023-11-07 Access To Advanced Health Institute Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
US9649370B2 (en) 2013-05-08 2017-05-16 Protatek International, Inc. Vaccine for PCV2 and mycoplasma
CN112999344A (zh) 2013-05-15 2021-06-22 阿尔伯达大学董事会 E1e2 hcv疫苗及使用方法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CN105473603B (zh) 2013-06-26 2019-10-25 北卡罗来纳-查佩尔山大学 用于登革病毒疫苗的方法与组合物
EP3016968B1 (fr) 2013-07-01 2019-06-26 Newsouth Innovations Pty Limited Diagnostic et traitement de maladies autoimmunes
ES2739123T3 (es) 2013-08-28 2020-01-29 Glaxosmithkline Biologicals Sa Nuevos antígenos y anticuerpos de la gripe
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
KR101977449B1 (ko) 2013-11-01 2019-05-10 유니버시티에트 이 오슬로 알부민 변이체 및 이의 용도
EP3068426B1 (fr) 2013-11-13 2020-02-12 University Of Oslo Vésicules de membrane externe et utilisation associées
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077434A2 (fr) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Immunogènes contre plusieurs pollens et procédés et utilisations pour moduler la réponse immunitaire
WO2015077442A2 (fr) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Immunogènes de pollen de graminée ainsi que procédés et utilisations pour la modulation de la réponse immunitaire
WO2015092710A1 (fr) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Administration simultanée controlatérale de vaccins
US11801223B2 (en) 2013-12-31 2023-10-31 Access To Advanced Health Institute Single vial vaccine formulations
EP3092302A4 (fr) 2014-01-06 2017-06-07 The United States of America, as Represented by the Secretary of Agriculture Salmonella enterica atténuée
MX2016009464A (es) 2014-01-21 2017-01-16 Immune Design Corp Composiciones para el uso en el tratamiento de afecciones alergicas.
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PL3096785T3 (pl) 2014-01-21 2021-03-08 Pfizer Inc. Kompozycje immunogenne zawierające skoniugowane antygeny sacharydów otoczkowych i ich zastosowania
WO2015123291A1 (fr) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Vaccin à base de pcsk9 et méthodes d'utilisation dudit vaccin
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (fr) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides dérivés de phl p, procédés et utilisations de ces derniers pour moduler une réponse immunitaire
EP3125931A4 (fr) 2014-04-03 2017-09-20 Biondvax Pharmaceuticals Ltd. Compositions de polypeptides multimères-multi-épitopes de grippe et leur production
KR102433464B1 (ko) 2014-05-28 2022-08-17 아게누스 인코포레이티드 항-gitr 항체 및 이의 사용 방법
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
WO2016014719A1 (fr) 2014-07-23 2016-01-28 Children's Hospital & Research Center Oakland Variants de protéines de liaison au facteur h et procédés d'utilisation de ceux-ci
ES2924988T3 (es) 2014-10-10 2022-10-13 Univ Michigan Regents Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
MX2017005524A (es) 2014-11-02 2018-01-26 Univ North Carolina Chapel Hill Metodos y composiciones para el virus del dengue recombinante para el desarrollo de vacunas y de diagnostico.
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
EP3229833A1 (fr) 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Procédé de traitement
WO2016109880A1 (fr) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Mimétiques de lipide a, procédés de préparation, et leurs utilisations
EP3244917B1 (fr) 2015-01-15 2023-04-19 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins antipneumococciques
WO2016134300A1 (fr) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Méthodes et compositions permettant d'utiliser la chlamydia atténuée en tant que vaccin et vecteur
CN107530416A (zh) 2015-03-05 2018-01-02 西北大学 非神经侵染的病毒及其用途
JP2018511655A (ja) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
AU2016236770B2 (en) 2015-03-26 2022-03-10 Gpn Vaccines Pty Ltd Streptococcal vaccine
RU2017140856A (ru) 2015-05-26 2019-06-26 Огайо Стейт Инновейшн Фаундейшн Стратегия вакцинации против вируса свиного гриппа вакциной на основе наночастиц
AU2016271857B2 (en) 2015-06-03 2020-05-28 Affiris Ag IL-23-P19 vaccines
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
JP2018522885A (ja) 2015-07-07 2018-08-16 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ ＩｇＥ介在性疾患の処置および予防のためのワクチン
MY192183A (en) 2015-07-21 2022-08-05 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US10323091B2 (en) 2015-09-01 2019-06-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
ES2607715B1 (es) 2015-10-01 2018-01-17 Solutex Na, Lcc Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
CN116063542A (zh) 2015-12-02 2023-05-05 阿吉纳斯公司 抗体和其使用方法
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
ES2811523T3 (es) 2016-01-19 2021-03-12 Pfizer Vacunas contra el cáncer
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
CA3017356A1 (fr) 2016-03-10 2017-09-14 Aperisys, Inc. Proteines de fusion se liant a un antigene et ayant des domaines hsp70 modifies
JP7155008B2 (ja) 2016-03-14 2022-10-18 ウニヴァーシテテット イ オスロ 変化されたＦｃＲｎを有する改変された免疫グロブリン
WO2017158421A1 (fr) 2016-03-14 2017-09-21 University Of Oslo Immunoglobulines anti-virales synthétiques
WO2017167768A1 (fr) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Nouvelle composition vaccinale
EP4112638A1 (fr) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation contenant un agoniste de tlr et procédés d'utilisation
WO2017201390A1 (fr) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Nouvelles compositions adjuvantes
MX2018014270A (es) 2016-05-21 2019-02-14 Infectious Disease Res Inst Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
SG10201912563XA (en) 2016-05-27 2020-02-27 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
MX2018014399A (es) 2016-06-01 2019-06-06 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
MX2019002178A (es) 2016-08-23 2019-09-18 Glaxosmithkline Biologicals Sa Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US11801290B2 (en) 2016-09-16 2023-10-31 Access To Advanced Health Institute Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
EP3518966A1 (fr) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions et méthodes de traitement d'une infection par hpv persistante
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
WO2018096396A1 (fr) 2016-11-22 2018-05-31 University Of Oslo Variants d'albumine et leurs utilisations
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2018132739A2 (fr) 2017-01-13 2018-07-19 Agenus Inc. Récepteurs de lymphocytes t qui se lient à ny-eso-1 et méthodes d'utilisation de ces derniers
CN110198735A (zh) 2017-01-20 2019-09-03 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
MX2019011599A (es) 2017-03-30 2019-12-19 Univ Queensland Moleculas quimericas y usos de las mismas.
CN110662557A (zh) 2017-03-31 2020-01-07 葛兰素史克知识产权开发有限公司 免疫原性组合物、用途和治疗方法
WO2018178265A1 (fr) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Composition immunogène, utilisation et procédé de traitement
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
MA50957A (fr) 2017-05-01 2020-10-14 Agenus Inc Anticorps anti-tigit et leurs méthodes d'utilisation
SG11201911930SA (en) 2017-06-11 2020-01-30 Molecular Express Inc Methods and compositions for substance use disorder vaccine formulations and uses thereof
WO2018232257A1 (fr) 2017-06-15 2018-12-20 Infectious Disease Research Institute Supports lipidiques nanostructurés et émulsions stables et leurs utilisations
IL300235A (en) 2017-07-18 2023-03-01 In3Bio Ltd Synthetic proteins and their therapeutic uses
EP3641808A1 (fr) 2017-08-14 2020-04-29 GlaxoSmithKline Biologicals S.A. Procédés d'amplification des réponses immunitaires
WO2019035963A1 (fr) 2017-08-16 2019-02-21 Ohio State Innovation Foundation Compositions à nanoparticules pour vaccins contre les salmonelles
AU2018326875A1 (en) 2017-09-04 2020-03-19 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
WO2019048928A1 (fr) 2017-09-07 2019-03-14 University Of Oslo Molécules de vaccin
EP3678695A1 (fr) 2017-09-08 2020-07-15 Infectious Disease Research Institute Formulations liposomales comprenant de la saponine et procédés d'utilisation
WO2019079594A1 (fr) 2017-10-18 2019-04-25 The University Of North Carolina At Chapel Hill Méthodes et compositions pour des vaccins contre les novovirus et le diqagnostic des novovirus
MX2020004543A (es) 2017-11-03 2020-09-18 Takeda Vaccines Inc Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
CN112638936A (zh) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
WO2020030572A1 (fr) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processus et vaccins
US20210220462A1 (en) 2018-08-23 2021-07-22 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3843782A1 (fr) 2018-08-29 2021-07-07 Centre Hospitalier Universitaire Vaudois (CHUV) Compositions de vaccin ebola et leurs procédés d'utilisation
WO2020051766A1 (fr) 2018-09-11 2020-03-19 上海市公共卫生临床中心 Immunogène pour vaccin à large spectre contre la grippe, et application de celui-ci
EP3890775A1 (fr) 2018-12-06 2021-10-13 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
JP2022513458A (ja) 2018-12-12 2022-02-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
EP3897846A1 (fr) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Méthodes d'induction d'une réponse immunitaire
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CN113573730A (zh) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 乙型肝炎免疫方案和组合物
CA3136278A1 (fr) 2019-04-10 2020-10-15 Pfizer Inc. Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues, kits les comprenant et leurs utilisations
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
CA3141577A1 (fr) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition et procede de sechage par atomisation d'une emulsion de vaccin et d'adjuvant
BR112021026132A2 (pt) 2019-06-25 2022-02-08 In3Bio Ltd Proteínas sintéticas quiméricas estabilizadas e usos terapêuticos das mesmas
JP2022542032A (ja) 2019-07-21 2022-09-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 治療用ウイルスワクチン
EP3770269A1 (fr) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification de glycosylation de bioconjugués
EP4010014A1 (fr) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Composition immunogène
US11680098B2 (en) 2019-08-30 2023-06-20 Agenus Inc. Antibodies that specifically bind human CD96
EP3799884A1 (fr) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
EP3808765A1 (fr) 2019-10-14 2021-04-21 ETH Zurich Lignée cellulaire pour la découverte et l'ingénierie tcr et leurs procédés d'utilisation
KR20220092572A (ko) 2019-11-01 2022-07-01 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그 방법
EP4058581A1 (fr) 2019-11-15 2022-09-21 Infectious Disease Research Institute Agoniste de rig-i et formulation d'adjuvant pour le traitement de tumeurs
NL2030835B1 (en) 2020-01-24 2022-12-29 Aim Immunotech Inc Methods, compositions, and vaccinces for treating a virus infection
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
CA3171864A1 (fr) 2020-02-21 2021-08-26 Pfizer Inc. Purification de saccharides
CN115605498A (zh) 2020-02-23 2023-01-13 辉瑞公司（Us） 大肠杆菌组合物及其方法
EP4114848A4 (fr) 2020-02-26 2024-04-03 Versitech Limited Vaccins à base de pd-1 dirigés contre une infection à coronavirus
AU2021252164A1 (en) 2020-04-09 2022-12-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
WO2021245611A1 (fr) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Protéines modifiées de spicule de coronavirus bêta
EP4171629A1 (fr) 2020-06-29 2023-05-03 GlaxoSmithKline Biologicals S.A. Adjuvants
KR20230083271A (ko) 2020-08-17 2023-06-09 유니버시타트 바셀 암 치료에 사용하기 위한 lfa-1 신호전달 매개체
CA3190375A1 (fr) 2020-08-24 2022-03-03 Natalie ANOSOVA Vaccins contre la covid-19 avec des adjuvants d'emulsion de squalene contenant du tocopherol
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
US20230416309A1 (en) 2020-10-23 2023-12-28 Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji Fusion protein and application thereof
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
KR20230097160A (ko) 2020-11-04 2023-06-30 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
WO2022101745A2 (fr) 2020-11-10 2022-05-19 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (fr) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes imitant la pcsk9 guidés par des anticorps et ne présentant pas de chevauchement de séquence de 9 résidus avec des protéines humaines
CA3208643A1 (fr) 2021-01-18 2022-07-21 Conserv Bioscience Limited Compositions immunogenes de coronavirus, methodes et utilisations de celles-ci
EP4032547A1 (fr) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Fragments dérivés du hsv 1 fce pour le traitement du hsv
IL305313A (en) 2021-02-19 2023-10-01 Sanofi Pasteur Recombinant meningococcal B vaccine
EP4294433A1 (fr) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Composition immunogène, utilisation et procédés
US20240165224A1 (en) 2021-03-26 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions
BR112023023671A2 (pt) 2021-05-28 2024-02-06 Pfizer Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
WO2023274860A1 (fr) 2021-06-28 2023-01-05 Glaxosmithkline Biologicals Sa Nouveaux antigènes de la grippe
WO2023020993A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020994A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020992A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023061993A1 (fr) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
CA3237496A1 (fr) 2021-11-18 2023-05-25 Matrivax, Inc. Compositions de proteines de fusion immunogenes et leurs procedes d'utilisation
WO2023135515A1 (fr) 2022-01-13 2023-07-20 Pfizer Inc. Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2023161817A1 (fr) 2022-02-25 2023-08-31 Pfizer Inc. Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
WO2023218322A1 (fr) 2022-05-11 2023-11-16 Pfizer Inc. Procédé de production de formulations de vaccin avec des conservateurs
WO2024110827A1 (fr) 2022-11-21 2024-05-30 Pfizer Inc. Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024110839A2 (fr) 2022-11-22 2024-05-30 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024116096A1 (fr) 2022-12-01 2024-06-06 Pfizer Inc. Formulations de vaccin pneumococcique conjugué

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
CA1331443C (fr) * 1987-05-29 1994-08-16 Charlotte A. Kensil Adjuvant a saponine
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
IE63692B1 (en) * 1987-11-03 1995-05-31 Syntex Inc Vaccine adjuvant
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0382271B1 (fr) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols comme adjuvants de vaccins
CA2017507C (fr) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant constitue d'une emulsion de gouttelettes submicron d'huile
NZ238731A (en) * 1990-06-27 1996-02-27 Univ Emory Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
BR9106604A (pt) * 1990-06-29 1993-06-22 Chiron Corp Composicao de vacina e processo para estimular uma resposta imunologica em um animal hospedeiro
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
JPH06501151A (ja) * 1990-09-28 1994-02-10 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ｇｐ１６０の誘導体およびアジュバントを含有するｇｐ１６０またはその誘導体に基づくワクチン
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5585103A (en) 1991-07-25 1996-12-17 Idec Pharmaceutical Corporation Induction of cytotoxic T-lymphocyte responses
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
ATE188613T1 (de) * 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
HU219056B (hu) * 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
US5723130A (en) * 1993-05-25 1998-03-03 Hancock; Gerald E. Adjuvants for vaccines against respiratory syncytial virus
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen

Also Published As

Publication number Publication date
DE122008000055I1 (de) 2009-02-19
EP0735898A1 (fr) 1996-10-09
CY2593B2 (en) 2009-11-04
US20060182753A1 (en) 2006-08-17
ES2219837T3 (es) 2004-12-01
DE69434956T2 (de) 2008-01-17
LU91486I2 (fr) 2008-12-15
CN1138298A (zh) 1996-12-18
US6146632A (en) 2000-11-14
ES2129801T3 (es) 1999-06-16
US6623739B1 (en) 2003-09-23
NZ329661A (en) 2005-03-24
WO1995017210A1 (fr) 1995-06-29
DE69417063D1 (de) 1999-04-15
AU687494B2 (en) 1998-02-26
SG49257A1 (en) 1998-05-18
CY2530B1 (en) 2006-04-12
AU1316695A (en) 1995-07-10
HK1012243A1 (en) 1999-07-30
DK0868918T3 (da) 2004-08-16
EP1792628A1 (fr) 2007-06-06
DE69417063T2 (de) 1999-10-28
EP1327451B1 (fr) 2007-04-18
CA2179779A1 (fr) 1995-06-29
ES2285036T3 (es) 2007-11-16
US7029678B2 (en) 2006-04-18
DE69433750D1 (de) 2004-06-03
NZ277802A (en) 1998-04-27
DK0735898T3 (da) 1999-08-23
US7510698B2 (en) 2009-03-31
JP4125781B2 (ja) 2008-07-30
US20070134268A1 (en) 2007-06-14
JPH09506887A (ja) 1997-07-08
AU6803198A (en) 1998-07-09
SG73578A1 (en) 2000-06-20
HK1057991A1 (en) 2004-04-30
JP2006249080A (ja) 2006-09-21
AU6803298A (en) 1998-07-09
ATE265228T1 (de) 2004-05-15
NL300363I1 (nl) 2009-01-05
CA2179779C (fr) 2010-04-20
EP0868918B1 (fr) 2004-04-28
PT868918E (pt) 2004-08-31
DE69434956D1 (de) 2007-05-31
EP0868918A3 (fr) 2000-04-26
JP4126067B2 (ja) 2008-07-30
EP0735898B1 (fr) 1999-03-10
GB9326253D0 (en) 1994-02-23
SI0868918T1 (en) 2004-08-31
WO1995017209A1 (fr) 1995-06-29
SI1327451T1 (sl) 2007-08-31
US20040043038A1 (en) 2004-03-04
JP4126079B2 (ja) 2008-07-30
EP0868918A2 (fr) 1998-10-07
GR3029750T3 (en) 1999-06-30
CN1086589C (zh) 2002-06-26
DK1327451T3 (da) 2007-08-20
EP1327451A1 (fr) 2003-07-16
ZA9410176B (en) 1995-11-17
AU705519B2 (en) 1999-05-27
PT1327451E (pt) 2007-07-23
HK1021504A1 (en) 2000-06-16
NL300362I1 (nl) 2009-01-05
DE122008000054I1 (de) 2009-02-19
ATE359818T1 (de) 2007-05-15
DE69433750T2 (de) 2005-08-04
AU705521B2 (en) 1999-05-27
ATE177322T1 (de) 1999-03-15
JP2007231029A (ja) 2007-09-13
US7169391B2 (en) 2007-01-30
KR100350965B1 (ko) 2003-02-25
AU1316495A (en) 1995-07-10
SI0735898T1 (en) 1999-06-30

Similar Documents

Publication Publication Date Title
LU91485I2 (fr) Vaccin adjuvant grippal dans lequel l'adjuvant estune émulsion huile-dans-eau comprenant du squalèn e, du DL-a-tocophérol et du polysorbate 80
AU4897590A (en) Tocols as adjuvant in vaccine
ES2138588T3 (es) Composiciones de vacunas que contienen liposomas.